Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13), RDHL: 12.22 (-0.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), ARGS: 9.65 (+0.34), NVO: 43.80 (+1.08), IDRA: 3.89 (+0.02), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), CBMG: 12.98 (+0.19), CELGZ: 3.34 (-0.01)
DynaVax Technologies: The Small Cap Gem Focus Stock Of The Week
Bret Jensen - at Seeking Alpha - Wed Dec 10, 2:02PM CST
DVAX: 15.35 (+0.30)
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:20PM CST
Dynavax Technologies Corp. (DVAX) announced that the company has amended its existing research and license agreement with AstraZeneca plc (AZN).
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15)
Dynavax to advance TLR9 Agonist into Phase 2a asthama clinical study in partnership with AstraZeneca
M2 - Tue Dec 09, 6:28AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
DVAX: 15.35 (+0.30)
Dynavax Announces Webcast of R&D Day
Marketwired - Tue Dec 09, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the application of toll-like receptor (TLR) biology, including updates on its Phase 3 investigational adult hepatitis B vaccine, HEPLISAV-B(TM), clinical programs in cancer and asthma, and advancing preclinical candidates. The webcast of the presentations and Q&A will begin at 8:30 a.m. ET and is scheduled to conclude at 11:00 a.m. ET.
DVAX: 15.35 (+0.30)
Dynavax to initiate asthma trial
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 9:55AM CST
DVAX: 15.35 (+0.30), AZN: 70.44 (+0.26)
Global Ragweed Allergy Clinical Trials Review, H2, 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/g87gqk/ragweed_allergy) has announced the addition of the "Ragweed Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Ragweed Allergy Global Clinical Trials Review, H2, 2014" provides data on the Ragweed Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ragweed Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ragweed Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Circassia Pharmaceuticals plc - Dynavax Technologies Corporation - Merck & Co., Inc. - ALK-Abello A/S - UCB S.A. - Greer Laboratories, Inc. - Curalogic A/S (Inactive) - Biothera, Inc. - Antigen Laboratories - Anergis SA Clinical Trial Overview of Top Institutes / Government - Azienda Ospedaliera L. Sacco - Mahidol University - The National Institute of Allergy and Infectious Diseases - University of Chicago - Rambam Health Care Campus For more information visit http://www.researchandmarkets.com/research/g8...ed_allergy
DVAX: 15.35 (+0.30), MRK: 57.46 (+0.25)
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study
Marketwired - Mon Dec 08, 5:00AM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced that the Company and AstraZeneca AB ("AstraZeneca"
DVAX: 15.35 (+0.30)
Global Hepatitis B Clinical Trials Market Review H2 2014 Report at ReportsnReports.com
PRWeb - Wed Dec 03, 2:38AM CST
The clinical trial report "Hepatitis B Global Clinical Trials Review H2 2014" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. Complete Report on Aspergillosis Clinical Trials Review Report Available @ http://www.reportsnreports.com/reports/319731...-2014.html .
DVAX: 15.35 (+0.30), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)
Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:20PM CST
Dynavax (DVAX) regained full rights to the development of its experimental therapeutic candidate, DV1179, following the expiration of its collaboration agreement with GlaxoSmithKline.
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 15.35 (+0.30), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ASMB: 7.95 (-0.07), GSK: 42.85 (+0.11), SVA: 4.95 (+0.07)
Glaxo backs out of development deal with Dynavax
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 6:41AM CST
DVAX: 15.35 (+0.30), GSK: 42.85 (+0.11)
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Collaboration With GSK
Marketwired - Fri Nov 28, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9. This resulted from the expiration of the Research and Development Collaboration and License Agreement with GSK originally executed in 2008. Dynavax will now have global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications.
DVAX: 15.35 (+0.30)
Cramer's Lightning Round - Noble Is A Good Oil Company (11/21/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Nov 23, 5:38AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday November 21. Bullish Calls: Popeyes Lousiana Kitchen (NASDAQ: PLKI ): Cramer prefers Popeyes to Wendy's. Noble Energy (NYSE: NBL ): "It...
DVAX: 15.35 (+0.30), KMI: 42.01 (+0.10), NBL: 48.50 (-0.48), TKMR: 13.97 (+0.14), PBA: 35.74 (-0.23), PLKI: 55.50 (+0.01), WEN: 8.99 (+0.14)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 15.35 (+0.30), BAX: 74.45 (-0.04), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), SVA: 4.95 (+0.07)
Dynavax's Heplisav Phase III Trial Recommended to Continue - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:30PM CST
Positive news flowed in for Dynavax Technologies Corporation (DVAX) when the company announced that the independent Data and Safety Monitoring Board (DSMB) completed its first prespecified review of the ongoing phase III trial on Heplisav.
CYTK: 5.87 (+0.35), DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13)
Dean Foods and Toll Brothers are big market movers
AP - Mon Nov 10, 3:48PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
DVAX: 15.35 (+0.30), OREX: 5.98 (+0.01), RYN: 28.31 (unch), MRK: 57.46 (+0.25), CMCSK: 57.71 (+0.21), DF: 18.96 (-0.01), TOL: 32.74 (+0.36), CMCSA: 58.07 (+0.17)
Dynavax's board authorises one-for-ten reverse common stock split
M2 - Mon Nov 10, 7:45AM CST
Dynavax Technologies (NASDAQ
DVAX: 15.35 (+0.30)
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)
Marketwired - Mon Nov 10, 5:01AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its first prespecified review and has recommended that the study continue unchanged.
DVAX: 15.35 (+0.30)
Dynavax Announces One-for-Ten Reverse Stock Split
Marketwired - Fri Nov 07, 4:05PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it had completed a one-for-ten reverse split of its common stock, effective as of 5:00 pm Eastern Time today. Beginning with the opening of trading on November 10, 2014 the Company's common stock will trade on the NASDAQ Capital Market on a split-adjusted basis.
DVAX: 15.35 (+0.30)